Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
The medications were grouped into categories:According to research published in JAMA Network Open, the use of anti-obesity medications, including glucagon-like peptide-1 receptor agonists, was associated with lower incidence and recurrence of alcohol use disorder.
根据JAMA Network Open发布的研究，使用抗肥胖药物，包括胰高血糖素样肽-1受体激动剂，与酒精使用障碍的发生率和复发率降低相关联。
The study analyzed data from 14,053 eligible participants if they started using an anti-obesity medication between January 2022 and August 2023 and refilled the same medication during October or November 2023.
该研究分析了14,053名合格参与者的数据，如果他们在2022年1月至2023年8月间开始使用抗肥胖药物，并在2023年10月或11月期间重新购买了同一种药物。
Also Read: Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
还阅读：拜登提出为热门减肥药物提供医疗补充保险和医疗补助
The medications were grouped into categories:
药物被分成以下类别：
- Metformin, bupropion, and naltrexone.
- First-generation GLP-1 receptor agonists, including Novo Nordisk A/S' (NYSE:NVO) Victoza (liraglutide) and Eli Lilly And Co's (NYSE:LLY) Trulicity (dulaglutide)
- Second-generation GLP-1 receptor agonists, including Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide)
- 二甲双胍、文拉法韦和纳曲酮。
- 第一代GLP-1受体激动剂，包括诺和诺德(NYSE:NVO)的维库智（利拉鲁肽）和礼来(NYSE:LLY)的特若利智（度拉格鲁肽）
- 第二代GLP-1受体激动剂，包括礼来的泽邦（替鲁塞肽）和诺和诺德的维戈维（塞马鲁肽）
A new cohort study highlights a notable trend among participants in weight loss programs: a significant portion of individuals reduced their alcohol consumption after starting anti-obesity medications.
一项新的队列研究突显了减肥计划参与者之间的一个显着趋势：在开始使用抗肥胖药物后，有相当一部分人减少了饮酒量。
The findings suggest potential links between these medications and changes in alcohol use, with various factors influencing this behavior.
研究结果表明，这些药物与酒精摄入量的变化之间可能存在关联，各种因素影响着这种行为。
Among participants reporting alcohol use at baseline, nearly half (45.3%) reduced their alcohol consumption after beginning the weight loss treatment.
在初始阶段报告饮酒的参与者中，有近一半（45.3%）在开始减重治疗后减少了饮酒量。
Meanwhile, 52.4% reported no change, and 2.3% noted an increase.
同时，有52.4%报告没有改变，2.3%指出有增加。
Participants with higher levels of obesity or heavier drinking habits at the start of the study were more likely to reduce alcohol consumption.
研究开始时肥胖水平较高或饮酒习惯较重的参与者更有可能减少饮酒。
Those prescribed Wegovy or Zepbound or the combination of bupropion and naltrexone also showed a tendency to drink less. However, the association with bupropion and naltrexone became statistically insignificant when adjusted for weight loss.
那些被开具Wegovy、Zepbound或bupropion和naltrexone组合的药物的患者也倾向于减少饮酒。然而，当根据减重进行调整时，bupropion和naltrexone的相关性变得在统计上不显著。
Researchers hypothesized that certain pharmacological properties of obesity drugs might influence alcohol use.
研究人员假设肥胖药物的某些药理特性可能会影响酒精使用。
For example, naltrexone reduces alcohol cravings, while GLP-1 RAs may diminish the rewarding effects of both alcohol and food. The study also noted that participants using metformin reported reduced alcohol consumption, possibly due to behavioral strategies emphasizing calorie reduction and the role of alcohol in impairing cognitive restraint.
例如，纳曲酮可以减少对酒精的渴望，而GLP-1 RAs可能减弱对酒精和食物的奖赏效应。研究还注意到使用二甲双胍的参与者报告减少了饮酒，可能是由于强调消耗卡路里减少以及酒精在损害认知控制方面的作用的行为策略。
The researchers acknowledged that the motivation to adopt healthier behaviors could be higher in individuals engaged in structured weight loss programs than those not seeking treatment.
研究人员承认，与未寻求治疗的人相比，参与受控减重计划的个体采用更健康行为的动机可能更高。
- Why Is Purple Biotech Stock Trading Higher On Monday?
- 紫色生物科技股票为何周一交易上涨？
Photo: Shutterstock
Photo: shutterstock
译文内容由第三方软件翻译。
